Biomarin Pharmaceutical Inc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomarin Pharmaceutical Inc with three other
companies in this sector in the United States:
sales of $1.12 billion
of which 94%
was Prescription Pharmaceuticals),
of which 100%
was Buprenorphine Based Drugs), and
Opko Health Incorporation
of which 83%
Biomarin Pharmaceutical Inc reported sales of $1.12 billion
December of 2016.
increase of 25.5%
versus 2015, when the company's sales were $889.90 million.
Sales at Biomarin Pharmaceutical Inc have increased during each of the previous five years
(and since 2011, sales have increased a total of 153%).
Sales of Vimizim saw an increase
that was more than double the company's growth rate: sales were up
55.2% in 2016, from
$228.15 million to $354.06 million.
Biomarin Pharmaceutical Inc also saw significant increases in sales in
Kuvan (up 45.4% to $348.01 million)
Not all segments of Biomarin Pharmaceutical Inc experienced an increase in sales in 2016:
sales of Aldurazyme fell 4.3% to $93.75 million.
Biomarin Pharmaceutical Inc also experienced decreases in sales in
Naglazyme (down 2.2% to $296.54 million)